for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arcturus Therapeutics Ltd

ARCT.OQ

Latest Trade

9.75USD

Change

-0.50(-4.88%)

Volume

20,331

Today's Range

9.63

 - 

10.32

52 Week Range

4.11

 - 

15.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.25
Open
10.32
Volume
20,331
3M AVG Volume
2.21
Today's High
10.32
Today's Low
9.63
52 Week High
15.49
52 Week Low
4.11
Shares Out (MIL)
10.72
Market Cap (MIL)
110.31
Forward P/E
-5.35
Dividend (Yield %)
--

Next Event

Arcturus Therapeutics Ltd at Biotechnology Industry Organization (BIO) Investor Forum Conference

Latest Developments

More

Arcturus Therapeutics Q2 Loss Per Share $0.07

Arcturus Therapeutics Announces Additional Registered Direct Offering Of Common Stock

Arcturus Therapeutics Says Co & Curevac Terminated Co-Development And Co-Commercialization Agreement Dated Jan 1, 2018

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arcturus Therapeutics Ltd

Arcturus Therapeutics Ltd. is a ribonucleic acid (RNA) medicines company. The Company owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.

Industry

Biotechnology & Drugs

Contact Info

10628 Science Center Dr Ste 200

+1.858.9002660

https://arcturusrx.com/

Executive Leadership

Peter C. Farrell

Chairman of the Board

Joseph E. Payne

President, Chief Executive Officer, Director

Andrew H. Sassine

Chief Financial Officer

Padmanabh Chivukula

Chief Operating Officer, Chief Scientific Officer

Kevin T. Skol

Senior Vice President - Business Development & Alliance Management

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-6.230

2017

-3.610

2018

-2.130

2019(E)

-1.628
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.33
Price To Book (MRQ)
5.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
46.17
LT Debt To Equity (MRQ)
46.17
Return on Investment (TTM)
-31.85
Return on Equity (TTM)
-22.27

Latest News

Latest News

BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics

* AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING

BRIEF-Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne

* JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE

BRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates

* ARCTURUS THERAPEUTICS FILES LAWSUIT AGAINST JOSEPH E. PAYNE AND HIS ASSOCIATES FOR VIOLATIONS OF FEDERAL SECURITIES LAWS

BRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGM

* JOSEPH E. PAYNE -ON APRIL 18, SENT LETTER TO ARCTURUS THERAPEUTICS LTD. BOARD TO RESTATE HIS PRIOR DEMAND TO CONVENE EGM OF SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2F05p2z) Further company coverage:

BRIEF-Joseph Payne Says Calling On Arcturus Therapeutics' Board To Hold EGM "Without Further Delay"

* JOSEPH PAYNE SAYS CALLING ON ARCTURUS THERAPEUTICS' BOARD TO HOLD ITS EXTRAORDINARY GENERAL MEETING "WITHOUT FURTHER DELAY"

BRIEF-‍Arcturus Therapeutics Initiates Lawsuit Against Former CEO Joseph Payne

* ARCTURUS THERAPEUTICS INITIATES LAWSUIT AGAINST FORMER PRESIDENT AND CEO JOSEPH PAYNE

BRIEF-Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders

* ARCTURUS THERAPEUTICS - CO SOUGHT TO APPOINT NEW INDEPENDENT AUDITOR IN ORDER TO REPORT FINANCIAL RESULTS, INCLUDING ITS FINANCIAL STATEMENTS FOR 2017

BRIEF-Arcturus Therapeutics Comments On Amended 13D Filing

* ARCTURUS THERAPEUTICS LTD - COMMENTED ON AMENDED 13D FILING BY JOSEPH E. PAYNE

BRIEF-Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics

* JOSEPH PAYNE SAYS EMAILED LETTER DATED FEBRUARY 12, REQUESTED BOARD OF ARCTURUS THERAPEUTICS CONVENE EXTRAORDINARY GENERAL MEETING AS SOON AS POSSIBLE

BRIEF-Certain Arcturus Therapeutics Shareholders Expressed Support For Former CEO Joseph Payne's Leadership

* FORMER CEO JOSEPH PAYNE SAYS HE WAS APPROACHED BY CERTAIN ARCTURUS THERAPEUTICS SHAREHOLDERS, WHO EXPRESSED SUPPORT FOR HIS CONTINUED LEADERSHIP

BRIEF-Arcturus Therapeutics Appoints Mark Herbert As Interim President

* ARCTURUS THERAPEUTICS APPOINTS MARK HERBERT AS INTERIM PRESIDENT

BRIEF-Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017

* BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING

BRIEF-Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics

* CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS

BRIEF-Arcturus Therapeutics Ltd Says Raised About $67.8 Million In Equity Financing

* ARCTURUS THERAPEUTICS LTD SAYS RAISED ABOUT $67.8 MILLION IN EQUITY FINANCING Source text for Eikon: (http://bit.ly/2qp3QZW) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up